Clinical Trials on Glabellar Crease

Total 10000 results

‹
1
2
3
4
5
6
7
8
9
10
...
199
200
›

Huons Co., Ltd.

Unknown

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Not yet recruiting

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Huons Biopharma

Recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines

Korea, Republic of
INIBIO Co., Ltd.

Completed

Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

Glabellar Lines

South Korea
Jetema USA Inc.

Completed

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines

United States
Allergan

Completed

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
AbbVie

Completed

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Puerto Rico
CKD Bio Corporation

Completed

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Glabellar Lines

Korea, Republic of
AbbVie

Completed

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

United States
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Hugel

Completed

To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

Glabellar Lines

Korea, Republic of
Hugel
Sihuan Pharmaceutical Limited

Completed

Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.

Glabellar Lines

Korea, Republic of
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Glabellar Lines

United States, Germany, Canada
Allergan

Completed

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

Glabellar Rhytides

China
Medy-Tox

Completed

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

Glabellar Lines
Mentor Worldwide, LLC
Quintiles, Inc.

Completed

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows (PT-03a)

Glabellar Rhytides

United States
Bonti, Inc.

Completed

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Glabellar Frown Lines (GL)

United States
Evolus, Inc.
Avania

Completed

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Glabellar Frown Lines

Germany
Eirion Therapeutics Inc.

Completed

AI-09 In Subjects With Glabellar Lines, GL-101

Glabellar Frown Lines

United States
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII) (BLESSIII)

Glabellar Frown Lines

United States
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (BLESS-II)

Glabellar Frown Lines

United States
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I (BLESS I)

Glabellar Frown Lines

United States, Germany, Poland
Evolus, Inc.
ethica Clinical Research Inc.

Completed

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Study Comparing Treatment With Alluzience vs Reconstituted Toxin (STAR)

Glabellar Frown Lines

Germany, United Kingdom
Medytox Korea

Completed

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Galderma R&D

Completed

Treatment of Moderate to Severe Glabellar Lines (READY-1)

Glabellar Frown Lines

United States, Canada
Galderma R&D

Completed

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines

Glabellar Frown Lines

Sweden
Galderma R&D

Completed

Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

Wrinkles | Glabellar Lines

United States
EuBiologics Co.,Ltd

Completed

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Unknown

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Glabellar Frown Lines
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Completed

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Ipsen

Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows (LAURITE 1)

Moderate to Severe Glabellar Lines

United States, Canada
Daewoong Pharmaceutical Co. LTD.

Completed

DWP450 for Treating Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Galderma R&D

Completed

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
EuBiologics Co.,Ltd

Completed

Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects

Moderate to Severe Glabellar Lines

Korea, Republic of
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

Glabellar Frown Lines | Frown Lines

United States
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

Glabellar Frown Lines | Frown Lines

United States
JHM BioPharma (Tonghua) Co. , Ltd.

Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Chongqing Claruvis Pharmaceutical Co., Ltd.

Recruiting

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

Australia
Galderma R&D

Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Glabellar Frown Lines | Canthal Lines

United States
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Chongqing Claruvis Pharmaceutical Co., Ltd.

Completed

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

China
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada, United Kingdom
Ipsen

Completed

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

Moderate to Severe Glabellar Lines

France, Germany
Serene Medical Inc

Completed

Efficacy Trial for the Reduction of Glabellar Lines

Rhytids in the Glabellar Region

United States

‹
1
2
3
4
5
6
7
8
9
10
...
199
200
›

Subscribe